Icon
+91 94997 68112
Login Register

Eliquis - (2.5, 5 mg; Tablet, Oral)

Apixaban BRISTOL MYERS SQUIBB
2.5, 5 mg; Tablet, Oral
More Than $1000 mn
More Than 5
More Than 5
More Than 5
More Than 5
More Than 5
 None
Used to reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients who have undergone hip or knee replacement surgery. Treatment of DVT or PE
Yes
******** ** ********* ** * ***** ******* ** *** ********* ********* *.*. ****** *** *******-***** ******. *********, *****, *******, *******, ************, *****, ******, *******, ********, *******, **********, *****, *********, ******, ******, ******, ********** (*****), ****, ***, ******, *********, *** & ***** ***** **** ** ** ******* ******* (*** **, ****) ** **** ******* (*** *, ****) & ******* (*** **, ****) ** *******. ***** ** **** ****** *** ** *** ***** ** ************ ** *** *** ********* ***** *** **** ** ** *** ***. **** ****** ***** **** ** ** *** ***** ** ******* ****, ******* ** ******'* ********* ** *******. *** ****** ****** **** ******* ** *** ****. ********** ** ******* **** ******, *******, ****, ******, ********, *** ***** , ******, **********(*****), ******** ******, *****, *********, ** *****'*, ***** *** ****** ***** *** ***** ** ********** *** *** *****. * ******* ********** *** ** ******** **** ***** ********* ** ****. ********* ** *** *** ****** ******** ****** ** ******** ****** ** ****. ** ** *** ****** ******** ** ****** ****** *** **** *.*. *** ***** ****** ******. *****, ********** ******* **** ********* *** ***** ******, ***** *** ***** ** ********** *** *** *****. *****, ***** ***** **** '***, '*** ****** *** ********* ** **********. **** '*** ****** ** ********* ** ******** **** *** *******. ** **** *, ****, *** ***** ** ******* *** *** ******* *******’* *** ******** *** *.*. ******** *****’* ****** **** ******** ******* *** *********** ** ****** (***) ****** (** *,***,***) *** *********** ****** (** *.***,***) ******** *******® ***** *** *********. **, *** ********* *** **** **** ***** *** ****** **** ***** *** ****, ***** ***** *** **** ******* **** ********* *** ****** **** ** ***** *, ****. *** **** - *** **, ****
Eliquis Patent 1 Patent 2 Patent 3
********* **** *** ******* *******
***** **** *** ******* *******
******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
********* *** \ *** *** *, **** ******* ******** ************ ** ***** *, ****
***** *** \ *** *** *, **** ******* ******** ************ ** ***** *, ****
******* *** \ *** *** *, **** ******* ******** ** ***** *, ****
  1. *** **, **** : ************, ***** & ****** ******** *** ********* *** **** ** ******* ******* (*** **, ****).
  2. *** **, **** : ******* (*** *, ****)- ** ****** *** ********* ****' *** ** **** ** ********* *** ********** ***** **, *** *** *** ******** *** **********.
  3. *** **, **** : ******* & ******* ******** *** ********* *** **** ** ******* ******* (*** **, ****).
  4. *** **, **** : ******* ******** *** ********* *** **** ** ******* ******* (*** *, ****) & ******* (*** **, ****)-** *******.
  5. *** **, **** : ******, ************, ***** ******** *** ********* *** **** ** ******* ******* (*** **, ****)-** ******.
  6. *** **, **** : ******* & ******* ******** *** ********* *** **** ** ******* ******* (*** **, ****).
  7. *** **, **** : ********* ******** *** ********* *** **** ** ******* ******* (*** *, ****) & ******* (*** **, ****).
  8. *** **, **** : *******, ******* ******** *** ********* *** **** ** ******* ******* (*** **, ****)-** ******.
  9. *** **, **** : ********* ******** *** ********* *** **** ** ******* ******* (*** *, ****) & ******* (*** **, ****)-** *******.
  10. *** *, **** : ************, ***** & ****** ******** *** ********* *** **** ** ******* ******* (*** **, ****).
  11. *** **, **** : ****** ******** *** ********* *** **** ** ******* ******* (*** *, ****) & ******* (*** **, ****)-** *******.
  12. *** **, **** : *** ******** *** ********* *** **** ** ******* ******* (*** **, ****)-** ******.
  13. *** *, **** : ********* ******** *** ********* *** **** ** ******* ******* (*** **, ****)-** ******.
  14. *** *, **** : *****, ******* ******** *** ********* *** **** ** ******* ******* (*** *, ****) & ******* (*** **, ****).
  15. *** *, **** : ***** ******** *** ********* *** **** ** ******* ******* (*** **, ****)-** ******.
  16. *** *, **** : ********, ****** ******** *** ********* *** **** ** ******* ******* (*** **, ****).
  17. *** *, **** : ********** (*****), *****, ********** ******** *** ********* *** **** ** ******* ******* (*** *, ****) & ******* (*** **, ****)-** *******.
  18. *** *, **** : ***** ******** *** ********* *** **** ** ******* ******* (*** *, ****) & ******* (*** **, ****)-** *******.
  19. *** *, **** : ****** ******** *** ********* *** **** ** ******* ******* (*** *, ****) & ******* (*** **, ****)-** *******.
  20. *** *, **** : *** ******** *** ********* *** **** ** ******* ******* (*** **, ****)-** ******.
  21. *** **, **** : **** ******** *** ********* *** **** ** ******* ******* (*** **, ****)-** ******.
  22. *** **, **** : ****** ******** *** ********* *** **** ** ******* ******* (*** *, ****) & ******* (*** **, ****)-** *******.
  23. *** **, **** : ****** ******** *** ********* *** **** ** ******* ******* (*** **, ****), ******* (*** *, ****) & ******* (*** **, ****)-** *******.
  24. *** *, **** : *** **** *********, *****, *******, *******, ************, *****, ******, *******, ******** ** ** ** ********.
  25. *** **, **** : *** **** *******, **********, *****, *********, ******, ******, ******, ******, **********, ****, ***, ******, *********, ***, ***** ** ** ** ********.
  26. *** **, **** : *** **** ***** ** ** ** ******** ******** ** **** ********.
  27. *** **, **** : *** ***** * **** ******* ******** ****** ** ******** ****** ***** **** ** **** ****** '*** (*** **, ****).
  28. *** *, **** : ********** ********* **** **** ***** *** ***** ** ********* *** *** *****.
  29. *** **, **** : ********** *** ********* **** ************
  30. *** *, **** : ********** ********* **** ****** ***** *** ***** ** ********* *** *** *****.
  31. *** **, **** : ********** ********* **** ****** ***** *** ***** ** ********* *** *** *****.
  32. *** **, **** : ********** ********* **** ******* ***** *** ***** ** ********* *** *** *****.
  33. *** **, **** : ********** ********* **** ******** ***** *** ***** ** ********* *** *** *****.
  34. *** **, **** : ********** ********* **** *** ******, ****** *** ****** ***** *** ***** ** ********* *** *** *****.
  35. *** **, **** : *** ***** * **** ******* ** *****'* ** ** *****'* ***** **** ** **** ****** ******* (*** *, ****).
  36. *** **, **** : ********** *** ********* **** *********
  37. *** **, **** : ***** ***** ** ********* **** **** ******.
  38. *** *, **** : ********** ********* **** **** ******(*****).
  39. *** *, **** : ********** ********* **** ******** ******.
  40. *** *, **** : ********** ********* **** ** *****'* *** *** *** ******* ** ****.
  41. *** **, **** : ********** ********* **** *****,***** & ********* *** *** *** ******* ** ****.
  42. *** **, **** : ********** ********* **** *****(*******) *** *** *** ******* ** ****.
  43. *** **, **** : ********** *** ********* **** ****** ********.
  44. *** **, **** : ********** *** ********* **** *****.
  45. *** *, **** : ********** *** ********* **** ******
  46. *** **, **** : ********** ********* **** ** *****'*
  47. *** **, **** : ********** ********* **** *********, ***** *** ***** ** ********* *** *** *****.
  48. *** *, **** : ********** ********* **** ***** ******, ***** *** ***** ** ********* *** *** *****.
  49. *** **, **** : ****** *** ********
  50. *** *, **** : ***** ***** **** '***, '*** ****** *** ********* ** **********. **** '*** ****** ** ********* ** ******** **** *** *******.
  51. *** *, **** : *** ***** ** ******* *** *** ******* *******’* *** ******** *** *.*. ******** *****’* ****** **** ******** ******* *** *********** ** ****** (***) ****** (** *,***,***) *** *********** ****** (** *.***,***) ******** *******® ***** *** *********. **, *** ********* *** **** **** ***** *** ****** **** ***** *** ****. ********* ** *** *** ****** *** ******* ******** *** *** ****** **** ** ***** *, ****.
  52. *** **, **** : ****** ******** *** ** ***** **** ** ******
  53. *** *, **** : ******* ******** *** ** ***** **** ** ******
  54. *** *, **** : *** **** ****** *** ******* **** ************ ** ****** '*** (*** **, ****)
  55. *** **, **** : *** *** ******* ******* ********** ** ******* *****.
  56. *** **, **** : *** *** ****** ******* ********** ** ******* *****.
  57. *** *, **** : ******* ******** *** ***** *** **** ** *******.
  58. *** **, **** : *** **** ******* **** ************ ** ****** **. '***.
  59. *** **, **** : *** ********* ********** ******* *******. ** ****** ** ** ** **********.
  60. *** **, **** : ******* (***(*)(*)) ******** *** ***** *** **** ** *******.
  61. *** **, **** : ***** ******* (*******) ************** *** ********* ********. ** ****** **** ***** ******* (*******) ************** *** ***** **** *** ** *** ****** ** *** **, ****.
  62. *** **, **** : *** **** ******* (***(*)(*)) **** ************ ** ****** **.'******* (*** **, ****).

Eliquis - (0.15MG)

Apixaban None
0.15MG
Less Than $1000 mn
None None
None None
None None
ELIQUIS is a factor Xa inhibitor indicated:  to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.  for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery.  for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy.  Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment.
Yes
Eliquis Patent 1 Patent 2
*** *********
******-********** ********* *** *********** ******* ** ****** ** ********** ******-********** ********* *** *********** ******* ** ****** ** ********** ******** ************ ******** ************

Eliquis - (5MG, 0.5MG)

Apixaban None
5MG, 0.5MG
Less Than $1000 mn
None None
None None
None None
ELIQUIS is a factor Xa inhibitor indicated:  to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.  for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery.  for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy.  Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment.
Yes
Eliquis Patent 1 Patent 2
*** *********
******-********** ********* *** *********** ******* ** ****** ** ********** ******-********** ********* *** *********** ******* ** ****** ** ********** ******** ************ ******** ************

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.